Geen internetverbinding — de opgeslagen versie van de pagina wordt getoond.

Arrowhead Pharmac…

USUSD
← Naar de Screener

Arrowhead Pharmaceuticals Inc (LSE:0HI3) — Biotechnology: Pharmaceutical Preparations. Aantal beurzen waarop de aandelen van het bedrijf worden verhandeld: 2. Op deze pagina — koers en grafiek, dividenden, grootste aandeelhouders en historiek van het aantal aandelen.

Over het Bedrijf

Website
arrowheadpharma.com
Sector
Health Care · Biotechnology: Pharmaceutical Preparations
Hoofdkantoor
Pasadena, United States
CEO
Christopher R. Anzalone
Werknemers
711
Opgericht
2004
Uitstaande Aandelen
141.25 mln. per 2026-07-30
Free Float
122.45 mln.
Marktkapitalisatie
9.22 mld. USD
Insiders
3.66%
Institutionele Beleggers
85.47%
Branche (SIC)
Pharmaceutical Preparations
ISIN
US04280A1007
LEI
549300O3CSB8T7OZ3D66
FCF
−75.1 mln. USD
Schuld
181 mln. USD
Winst en FCF — voor de 12 maanden tot 30.06.2026 (het laatste rapport van het bedrijf).
NAV
3.30 USD · P/NAV 20.0
Balance sheet date30.06.2026
Assets2.11 mld. USD
− Liabilities1.65 mld. USD
= Total equity466 mln. USD
− Non-controlling interests512 k USD
= NAV (aandelen van de aandeelhouders van het bedrijf)466 mln. USD
− Intangible assets5.59 mln. USD
= Tangible NAV460 mln. USD
Aandelen141 135 000
NAV per share3.30 USD
Tastbare NAV per Aandeel3.26 USD
Share price (0HI3)65.8200 USD
P/NAV19.95
NAV history
Balance sheet dateNAVNAV per share
30.06.2026466 mln. USD3.30 USD
31.03.2026614 mln. USD4.37 USD
31.12.2025568 mln. USD4.14 USD
30.09.2025466 mln. USD3.43 USD
30.06.2025522 mln. USD3.78 USD
31.03.2025683 mln. USD4.95 USD
31.12.202452.6 mln. USD0.42 USD
30.09.2024185 mln. USD1.49 USD
Beschrijving

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.

advertentie

Beurzen en Tickers

BeursTickerValutaPrijsType
US USA StocksARWR primairUSD58.37 +0.41%gewone aandelen
LSE London Stock Exchange0HI3 IOBUSD65.82 +0.00%gewone aandelen

Koers over 3 Maanden

stijgingsdag dalingsdagBeweeg over / tik op een dag — openings-, slot-, hoogste en laagste koers

Grootste Aandeelhouders

HouderBelangAandelenRapportdatum
Blackrock Inc.10.53%14.83 mln.2026-06-30
Avoro Capital Advisors L…8.06%11.36 mln.2026-06-30
FMR, LLC5.71%8.04 mln.2026-06-30
Vanguard Portfolio Manag…4.51%6.35 mln.2026-06-30
Vanguard Capital Managem…4.34%6.11 mln.2026-06-30
State Street Corporation4.04%5.69 mln.2026-06-30
iShares Trust-iShares Co…3.5%4.93 mln.2026-08-31
VANGUARD INDEX FUNDS-Van…3.01%4.25 mln.2026-06-30
NORGES BANK2.77%3.9 mln.2026-06-30
Invesco Ltd.2.76%3.88 mln.2026-06-30
ANZALONE CHRISTOPHER RIC…≈2.69%3.79 mln.2026-01-02
Geode Capital Management…2.51%3.53 mln.2026-06-30
Fred Alger Management, L…2.34%3.3 mln.2026-06-30
VANGUARD INDEX FUNDS-Van…2.18%3.07 mln.2026-06-30
Fidelity Mt. Vernon Stre…1.81%2.55 mln.2026-07-31
Invesco Exchange-Traded…1.27%1.79 mln.2026-08-31
VANGUARD INDEX FUNDS-Van…1.26%1.77 mln.2026-06-30
VANGUARD INDEX FUNDS-Van…1.15%1.61 mln.2026-06-30
SPDR SERIES TRUST-State…1.05%1.48 mln.2026-08-31
SPDR S&P MIDCAP 400 ETF…0.73%1.03 mln.2026-08-31
iShares Trust-iShares Bi…0.69%968 7382026-07-31
O'BRIEN PATRICK C (Chief…≈0.39%547 4082026-01-06
MYSZKOWSKI KENNETH ALLEN…≈0.32%455 4332025-01-07
HAMILTON JAMES C (Office…≈0.16%226 9582026-04-23
APEL DANIEL JOSEPH (Chie…≈0.12%162 9052026-04-22
GIVEN DOUGLAS BRUCE (Dir…≈0.09%124 1672024-12-17
PERRY MICHAEL S (Directo…≈0.08%111 4592026-08-18
FERRARI MAURO (Director)≈0.05%69 0532025-12-26
WADDILL WILLIAM D (Direc…≈0.04%56 5632025-12-19
LU HONGBO B (Director)≈0.04%52 0122026-05-12